Respiratory medicine
-
There is a lack of systematised information on respiratory sounds of healthy people. This impairs health professionals from differentiating respiratory sounds of healthy people from people with respiratory diseases, which may affect patients' diagnosis and treatment. Therefore, this systematic review aimed to characterise respiratory sounds of healthy people. ⋯ Respiratory sounds show different acoustic properties depending on subjects' characteristics, subjects' position, respiratory flow and place of recording. Further research with robust study designs, different populations and following the guidelines for computerised respiratory sound analysis are urgently needed to build evidence-base.
-
Respiratory medicine · Apr 2014
Randomized Controlled Trial Multicenter StudyEffect of QVA149 on lung volumes and exercise tolerance in COPD patients: the BRIGHT study.
QVA149 is a novel, inhaled, once-daily dual bronchodilator containing a fixed-dose combination of the long-acting β2-agonist indacaterol and the long-acting muscarinic antagonist glycopyrronium (NVA237), for the treatment of chronic obstructive pulmonary disease (COPD). This study evaluated the effects of QVA149 on exercise tolerance, hyperinflation, lung function and lung volumes versus placebo and tiotropium. ⋯ In patients with moderate-to-severe COPD, once-daily QVA149 significantly improved exercise endurance time compared with placebo which was associated with sustained reductions of lung hyperinflation as indicated by significant improvement in IC at rest and during exercise.
-
Respiratory medicine · Apr 2014
Randomized Controlled Trial Multicenter StudyStepwise withdrawal of inhaled corticosteroids in COPD patients receiving dual bronchodilation: WISDOM study design and rationale.
Long-acting bronchodilators in combination with inhaled corticosteroids (ICS) are recommended to decrease the risk of recurrent exacerbations in patients with Global initiative for chronic Obstructive Lung Disease (GOLD) stage 3-4 chronic obstructive pulmonary disease (COPD). There is increasing concern about the clinical benefit and long-term safety of ICS use in COPD patients. The WISDOM (Withdrawal of Inhaled Steroids During Optimised bronchodilator Management) study (NCT00975195) aims to evaluate the need for ICS use via stepwise withdrawal of ICS in COPD patients (GOLD 3-4 with a history of at least one exacerbation during the 12-month period prior to screening) receiving dual bronchodilation. ⋯ Lung function, symptoms and safety are also assessed. A sub-study aims to identify sub-populations and markers of steroid need. This study will determine the benefit of continued ICS therapy in combination with dual long-acting bronchodilators in COPD.
-
Respiratory medicine · Apr 2014
How does comorbidity influence survival in idiopathic pulmonary fibrosis?
Idiopathic pulmonary fibrosis (IPF) is the most common of the idiopathic interstitial pneumonias. It is a serious and progressive lung disease with a median survival of three years. The role of comorbidities in the prognosis of IPF is not clear. ⋯ These findings emphasize the need of careful diagnosis and treatment of comorbidities and their risk factors in patients with IPF. In the absence of efficient treatment options for the majority of patients diagnosed with IPF, this may play a role in the effort to optimize the survival of IPF patients. Further studies are needed to fully clarify the impact of comorbidities on prognosis in patients diagnosed with IPF.